Abstract 113P
Background
Patients (pts) with metastatic urothelial carcinoma (mUC) who do not experience disease progression after 4-6 cycles of first-line platinum-based chemotherapy (PBC) may benefit from immunotherapy as maintenance treatment with Avelumab, or receive Pembrolizumab as a second-line.
Methods
AVePEm is a multicenter, observational, retrospective study involving pts with mUC who did not progress after 4 cycles of PBC: GroupA received Avelumab and GroupB Pembrolizumab. The primary endpoints were overall survival (OS) and progression-free survival (PFS), with adverse events (AEs) as secondary endpoints. A p-value of <0.05 was considered significant.
Results
From August 2019 to July 2024, we identified 30 pts. Of those, 53% were in GroupA and 47% in GroupB. Most had transitional cell carcinoma, with 77% from the lower urinary tract and 47% having lymph node-only disease. The median number of PBC cycles was 6, with 40% ineligible for cisplatin. After a median follow-up of 19.9 months (mo) for GroupA and 18.7 mo for GroupB, the mOS was 25 mo and 29.5 mo, respectively (p=0.52) and the mPFS of immunotherapy was 14 mo and 8 mo, respectively (p=0.51). The median time from the end of PBC and the start of Pembrolizumab was 4.1 mo, with a median treatment duration of 7.6 mo for GroupA and 3.5 mo for GroupB. At the time of data analysis, 40% (n=12) of pts were alive and 33% (n=10) on treatment, with 40% still receiving Avelumab, and 50% and 10% on subsequent therapies after Avelumab and Pembrolizumab, respectively. In both groups 50% of pts have a neutrophil-to-lymphocyte ratio (NLR) ≥3 at baseline of PBC. NLR ratio negatively correlates with OS (p=0.099) and PFS (p=0.047). Both treatments were well tolerated, with Grade 3 AEs in 1 pt on Avelumab and 3 on Pembrolizumab, and no Grade 4 AEs reported.
Conclusions
Group A and Group B showed no statistically significant differences in OS and PFS. Of note, more pts were on Avelumab treatment at the data cutoff. AEs were similar in the two groups. Further investigation and follow-up are warranted to gain definitive conclusions on optimal mUC management in the era of immunotherapy and immunoconjugates.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Pastorelli: Financial Interests, Personal, Advisory Role: MSD Oncology, Amgen, Ipsen, Novartis, Pfizer, Astellas, Leo Pharma, GSK, AbbVie, Bayer. M. Milella: Financial Interests, Personal, Advisory Role: AstraZeneca, MSD Oncology, Janssen Oncology; Financial Interests, Personal, Research Funding: Roche; Financial Interests, Personal, Funding: Ipsen, Servier, Viatris; Financial Interests, Personal, Other: Novartis, Oncosil. All other authors have declared no conflicts of interest.
Resources from the same session
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
Resources:
Abstract
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract